Ella Easterling
Nurse Practitioner · Oklahoma City, OKNPI 1841785268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,221 and has fallen 86.6% since, to $297 in 2025. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$980
- Alkermes, Inc.$754
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$543
- Otsuka America Pharmaceutical, Inc.$538
- AbbVie$517
- Vanda Pharmaceuticals Inc.$496
- plus $1K from 8 others
What the payments were for
- Food & beverage$4,76895%
- Education$2335%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 58 | $980 |
| Alkermes, Inc. | 36 | $754 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $543 |
| Otsuka America Pharmaceutical, Inc. | 39 | $538 |
| AbbVie | 45 | $517 |
| Vanda Pharmaceuticals Inc. | 23 | $496 |
| Teva Pharmaceuticals USA, Inc. | 26 | $375 |
| Indivior Inc. | 16 | $253 |
| Sunovion Pharmaceuticals Inc. | 34 | $201 |
| Neurocrine Biosciences, Inc. | 8 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Lundbeck LLC | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Axsome Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$124
- INVEGA SUSTENNA$119
- VRAYLAR$111
How this compares
$5,001 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 33 | $105,250 |
| VraylarCariprazine Hcl | 42 | $62,918 |
| AristadaAripiprazole Lauroxil | 18 | $56,579 |
| PerserisRisperidone | 21 | $48,765 |
| RexultiBrexpiprazole | 25 | $47,176 |
| Lurasidone Hcl | 64 | $6,909 |
| Quetiapine Fumarate | 146 | $4,096 |
| Buspirone Hcl | 107 | $2,586 |
| Doxepin Hcl | 36 | $1,880 |
| Aripiprazole | 63 | $1,845 |
| Hydroxyzine Hcl | 37 | $1,748 |
| Hydroxyzine Pamoate | 35 | $1,677 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $1,650 |
| Propranolol Hcl | 70 | $1,533 |
| Ziprasidone Hcl | 14 | $1,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $980 | $105,25033 claims |
| AbbVieVraylar | $517 | $62,91842 claims |
| Alkermes, Inc.Aristada | $754 | $56,57918 claims |
| Indivior Inc.Perseris | $253 | $48,76521 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $538 | $47,17625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Oklahoma City
- Sara GoreOklahoma City$52K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Janelle WagnerOklahoma City$13K
- Stefanie RollinsOklahoma City$13K
- Lacey CampbellOklahoma City$13K
- Stacey Waggoner FisherOklahoma City$9K
- Karie StewartOklahoma City$9K
- Lori CraigOklahoma City$8K
- Jennifer LewisOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.